Literature DB >> 6193772

Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial.

.   

Abstract

The Idiopathic Neovascularization Study is a multicenter controlled clinical trial designed to determine whether argon laser photocoagulation is useful in preventing severe visual loss in eyes with a choroidal neovascular membrane (NVM) and no other clinically significant eye disease. Patients with an NVM 200 to 2,500 microns from the center of the foveal avascular zone were randomly assigned to argon laser photocoagulation (n = 33) or to observation (n = 34) groups. While the sample size of 67 eyes is insufficient to yield independent, definitive results, the pattern of treatment benefit is similar to that observed in two other controlled trials of argon laser photocoagulation of NVMs, the Senile Macular Degeneration Study and the Ocular Histoplasmosis Study. It is reasonable to conclude that patients with idiopathic NVMs, treated according to study protocol, may derive a similar benefit.

Entities:  

Mesh:

Year:  1983        PMID: 6193772     DOI: 10.1001/archopht.1983.01040020360003

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  11 in total

1.  The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients.

Authors:  C J Flaxel
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

2.  The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.

Authors:  Frank A Sloan; Brian W Hanrahan
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

3.  Idiopathic sub-retinal neovascular membranes in the macula (hemorrhagic macular choroidopathy of young adults). Clinical report and effectiveness of laser treatment.

Authors:  F G Bottoni; A F Deutman
Journal:  Doc Ophthalmol       Date:  1986       Impact factor: 2.379

4.  Surgical removal of idiopathic, myopic and age-related subfoveal neovascularization.

Authors:  F Bottoni; P Airaghi; E Perego; S Ortolina; G Carlevaro; V De Molfetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

5.  Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.

Authors:  Barbara S Hawkins; Neil M Bressler; Susan B Bressler; Frederick H Davidorf; John C Hoskins; Marta J Marsh; Päivi H Miskala; Maryann Redford; Paul Sternberg; Matthew A Thomas; Cynthia A Toth
Journal:  Arch Ophthalmol       Date:  2004-11

6.  Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-01

7.  Diffusion of technologies for the care of older adults with exudative age-related macular degeneration.

Authors:  Joshua D Stein; Brian W Hanrahan; Grant M Comer; Frank A Sloan
Journal:  Am J Ophthalmol       Date:  2012-12-06       Impact factor: 5.258

8.  Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.

Authors:  Xiaojuan Fan; Ning Gao; Jingming Li; Jianqin Lei; Qianyan Kang
Journal:  Mol Cell Biochem       Date:  2017-09-07       Impact factor: 3.396

9.  Pegaptanib for myopic choroidal neovascularization in a young patient.

Authors:  Michael D Bennett; Wendy Yee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.535

10.  Peripapillary Neovascular Membrane in a Young Pregnant Woman and Prompt Response to Ranibizumab Injections following Uneventful Delivery.

Authors:  Konstantinos Anastasilakis; Chrysanthos Symeonidis; Konstantinos Kaprinis; Asimina Mataftsi; Argyrios Tzamalis; Stavros A Dimitrakos
Journal:  Case Rep Ophthalmol       Date:  2011-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.